What one share of SELLAS Life Sciences Group holds
We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and SLS009 (tambiciclib), a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
SELLAS Life Sciences Group’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.21 |
|---|---|
| Cash and investments | $0.69 |
| Book value | $0.68 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$933.13 | $0.32 | −$625.71 | — | −$196.97 |
| 2017 | — | −$521.91 | — | — | — | — |
| 2018 | — | −$157.72 | — | — | — | $11.91 |
| 2019 | — | −$10.92 | — | — | — | $1.20 |
| 2020 | $0.24 | −$2.11 | — | — | — | $1.96 |
| 2021 | $0.49 | −$1.34 | — | — | — | $1.28 |
| 2022 | $0.05 | −$2.13 | — | — | — | $0.23 |
| 2023 | $0.00 | −$1.34 | — | — | — | −$0.25 |
| 2024 | — | −$0.50 | — | — | — | $0.13 |
| 2025 | — | −$0.25 | — | — | — | $0.46 |
Common questions about SELLAS Life Sciences Group
How much does one share of SELLAS Life Sciences Group earn?
Over the last 12 months, SELLAS Life Sciences Group lost $0.21 for each share.
Does SELLAS Life Sciences Group pay a dividend?
SELLAS Life Sciences Group didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is SELLAS Life Sciences Group’s book value per share?
SELLAS Life Sciences Group’s book value is $0.68 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of SELLAS Life Sciences Group have?
Each share of SELLAS Life Sciences Group has $0.69 of cash and investments, as of June 30, 2026.
Has SELLAS Life Sciences Group bought back shares?
SELLAS Life Sciences Group’s share count rose about 575428% from 2016 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.